Urinary HPV testing may offer hope for cervical screening non-attenders

D A Blake¹, E J Crosbie^{2

3}, S Kitson³

Affiliations

¹ Department of Obstetrics and Gynaecology, St James's University Hospital, Leeds, UK.
² Department of Obstetrics and Gynaecology, St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
³ Gynaecological Oncology Research Group, Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, St Mary's Hospital, University of Manchester, Manchester, UK.

Comment

D A Blake et al. BJOG. 2017 Aug.

. 2017 Aug;124(9):1364.

doi: 10.1111/1471-0528.14683.

D A Blake¹, E J Crosbie^{2

3}, S Kitson³

¹ Department of Obstetrics and Gynaecology, St James's University Hospital, Leeds, UK.
² Department of Obstetrics and Gynaecology, St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
³ Gynaecological Oncology Research Group, Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, St Mary's Hospital, University of Manchester, Manchester, UK.

No abstract available

Comment on

HPV testing in first-void urine provides sensitivity for CIN2+ detection comparable with a smear taken by a clinician or a brush-based self-sample: cross-sectional data from a triage population.
Leeman A, Del Pino M, Molijn A, Rodriguez A, Torné A, de Koning M, Ordi J, van Kemenade F, Jenkins D, Quint W. Leeman A, et al. BJOG. 2017 Aug;124(9):1356-1363. doi: 10.1111/1471-0528.14682. BJOG. 2017. PMID: 28391609 Clinical Trial.